ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / CRVO / insiders
SHPH (41) MIRA (36) IMMP (47) CELU (26) ⌘ Pro Terminal β†’

CervoMed Inc. (CRVO) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$1.64 +2.50% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.64

CervoMed Inc. (CRVO) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $24.2M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CRVO Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is CRVO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, CervoMed Inc. (NASDAQ: CRVO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $1.64 (+2.50% 1D, market cap $24.2M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CRVO ranks #868 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does CRVO compare to SHPH and MIRA in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CRVO carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, SHPH (Shuttle Pharmaceuticals Holdings Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $24.5M) and MIRA (MIRA Pharmaceuticals Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $23.0M). Among the 5-stock peer group, CRVO leads on earnings multiple (N/A) while CRVO leads on capital efficiency (-35.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CRVO?
β–Ό

Per CRVO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001053691), CervoMed Inc. generated $4.0M in revenue (-58.9% YoY), -$27.0M in net income, and -$23.4M in free cash flow against $22.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.64 (+0.26%)🧬 Dilution Drag (+1.28% YoY Shares)βš™οΈ Cash Engine: 7/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (28/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-10.0% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510028
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D-
Cash (7)Whales (3)SEC (8)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-13.4% Base Target
$11 Bull$1 Base$1 Bear
πŸ“¬ FREE CRVO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for CRVO)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (28/100 Composite)
πŸ” WHY CRVO SCORES 28/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 2/9

β–² #2 Bullish Driver: Cash Engine Quality+7/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
36
Grade E$2.27+0.9% Next Q
Q2 (-2Q)
33
Grade E$2.29-3.1% Next Q
Q3 (-1Q)
31
Grade E$2.22-26.1% Next Q
Current
28
Grade E$1.64-10% Hist 90D Ξ±
Trajectory: E (36) β†’ E (28)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a CRVO Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While CRVO currently carries a cautious 28/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.51) and Max Pain ($1.72) forces dealer call-delta covering toward $10.50.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CRVOβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œCRVO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 28%NO 72%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

CRVO Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (CRVO)

No recent open-market Form 4 cluster sales or emergency dumps flagged on CRVO. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CRVO)

  • βœ“Walkthrough of CRVO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
CRVO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -55.68%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-03O $1.75H $1.75L $1.60C $1.64VOL 585.4K
RES: $3.56SUP: $1.56SMA50: $2.51SMA200: $3.45
$8.24$6.44$4.64$2.84$1.04RES $3.56SUP $1.56$1.642026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CRVO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ CRVO Butterfly Map β†’ + Track CRVO β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -58.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CRVO today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for CRVO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CRVO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CRVO)

Health Care Rank #868 of 1015 βš”οΈ SHPH vs CRVO Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (CRVO vs. SHPH, MIRA, IMMP, CELU)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, CervoMed Inc. (CRVO) ranks #868 by composite RQD confidence (28/100, grade E) and #820 by equity capitalization ($24.2M). Within this direct 5-issuer industry benchmark cohort, CRVO leads on earnings valuation at N/A trailing P/E, while CRVO leads on capital efficiency and profitability with -35.0% ROIC and β€” gross margin. IMMP currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with CRVO at 28/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CRVO ACTIVE
CervoMed Inc.
E 28/100 β€” β€” -35.0% +2.50% $24.2M Benchmark Subject
SHPH
Shuttle Pharmaceuticals Holdings Inc.
D- 41/100 β€” β€” -35.0% -3.88% $24.5M /shph-vs-crvo β†’
MIRA
MIRA Pharmaceuticals Inc.
D- 36/100 β€” β€” -35.0% -2.06% $23.0M /mira-vs-crvo β†’
IMMP
Immutep Limited
D 47/100 β€” β€” β€” +0.33% $22.6M /immp-vs-crvo β†’
CELU
Celularity Inc. (Class A)
E 26/100 β€” 24.4% -35.0% +0.30% $26.0M /celu-vs-crvo β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001053691 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), CervoMed Inc. (CRVO) reported GAAP revenue of $4.0M (-58.9% vs. FY2024 revenue of $9.7M , and -43.9% cumulative change since FY2023) , GAAP net income of -$27.0M, operating cash flow of -$23.4M, and free cash flow of -$23.4M (-41.9% YoY). On the balance sheet, CRVO closed FY2025 with $22.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $4.0M -$27.0M -$23.4M -$23.4M $22.9M β€”
FY2024 (FY) 2024-12-31 $9.7M -$16.3M -$16.5M -$16.5M $43.1M β€”
FY2023 (FY) 2023-12-31 $7.1M -$2.2M -$7.4M -$7.4M β€” β€”

3. CRVO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CRVO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, CervoMed Inc. (NASDAQ: CRVO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $1.64 (+2.50% 1D, market cap $24.2M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CRVO ranks #868 in composite RQD confidence.

How does CRVO compare to SHPH and MIRA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CRVO carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, SHPH (Shuttle Pharmaceuticals Holdings Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $24.5M) and MIRA (MIRA Pharmaceuticals Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $23.0M). Among the 5-stock peer group, CRVO leads on earnings multiple (N/A) while CRVO leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CRVO?

Per CRVO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001053691), CervoMed Inc. generated $4.0M in revenue (-58.9% YoY), -$27.0M in net income, and -$23.4M in free cash flow against $22.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CRVO trading relative to its 50-day, 200-day, and 52-week technical levels?

CRVO last traded at $1.64 (+2.50% on volume of 286,879 shares), positioning the stock -34.66% below its 50-day simple moving average ($2.51) and -52.46% below its 200-day simple moving average ($3.45). Across its 52-week range of $1.60 to $10.00, CRVO sits at the 0.5% percentile with a 14-day RSI of 28.2 (OVERSOLD (<32)) and an implied next-earnings move of Β±12.5% ($1.44 to $1.84).

Direct Sub-Reports: CRVO RQD Cockpit CRVO 12M Forecast CRVO Earnings & Move CRVO Dividends & DRIP CRVO Insiders & 13F CRVO Whale Options CRVO Profit Sankey CRVO News & Why
ROARABLE RATING BRIEF β€’ RQD 28/100 (E) βœ“ SEC XBRL & RQD VERIFIED

CRVO β€” CervoMed Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

CervoMed Inc. (CRVO) earns a live Roarable RQD composite score of 28/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.64 (+2.50% 1D, market capitalization $24.2M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of β€”, operating margin of -60.0%, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

CervoMed Inc. (CRVO) is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations.. Specific products, customers, and revenue model details are β€” Reported revenue across FY 2023–FY 2025 is shown in the Financial Trend section.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), CervoMed Inc. (CRVO) reported $4.0M in annual revenue (up from $9.7M in FY2024, -58.9% YoY) and -$27.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($7.1M revenue, -$2.2M net income) through FY2025, CRVO scaled operating cash flow to -$23.4M and free cash flow to -$23.4M, backed by $22.9M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 28/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 3/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.60 – $10.00 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are β€” A prospective investor should note that the sector and industry classification alone does not establish any specific supplier, customer, or peer linkage in the source data.

  • Key Question #1: Can CRVO sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $4.0M and free cash flow of -$23.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is CRVO's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CRVO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for CervoMed Inc. (CRVO) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to CRVO Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CRVO Bull vs. Bear Conversation Board β€” What's Your Call at $1.64?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CRVO 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CRVO:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER β€’ FCF Compounder Hunter πŸ‚ BULLISH 🎯 Target: $1.89 (+18.1%)
πŸ“Œ Pinned Debate

Recent news flow includes an H.C. Wainwright Buy reiteration and a GREEN-flagged Q2 2026 earnings item describing a narrower-than-expec

Here is why I am bullish on CRVO here at $1.60: Recent news flow includes an H.C. Wainwright Buy reiteration and a GREEN-flagged Q2 2026 earnings item describing a narrower-than-expected loss.. Compare CRVO's -60.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $1.52 are getting bought.

CapAlloc_Nerd πŸ‚ BULL

@CashFlowKing Agree on the RQD 28/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.60 and keeping dry powder in case we test $1.49.

CR CreditSpread_Watch RQD DEBATE OPENER β€’ Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $1.20 (-25.0%)
Spot @ $1.60

FY 2025 revenue fell to $4.0M from $9.7M while operating loss widened to -$28.3M, with ROIC at -35% and a 2/9 Piotroski F-Score.

I respect the product at CervoMed Inc., but the stock at $1.60 is a different story. FY 2025 revenue fell to $4.0M from $9.7M while operating loss widened to -$28.3M, with ROIC at -35% and a 2/9 Piotroski F-Score.. FCF yield is 0.0% and RQD sits at 28/100 (E) β€” why pay up here when you can wait for next quarter's numbers?

LIVE TAPE